PF-Atlas › Clinical Trials › NCT05437120
Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
VX-121/TEZ/D-IVA · Phase 1
Registry ID
NCT05437120
Phase
Phase 1
Status
Completed
Drug / intervention
VX-121/TEZ/D-IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2022-07-22
About this trial
VX-121/TEZ/D-IVA is evaluated in NCT05437120, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05437120 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.